Reviews past records of older adults with spreading colon cancer receiving chemotherapy
Looks back at chemotherapy with antibody treatment in adults 70 and older with colon cancer.
Key facts
- Who runs it
- Matteo Clavarezza
- Where
- Genoa and Genova, ItalySee the 2 sites
- Trial code
- Registry title
- COLON ERDERLY LOW DOSE
- Status
- Recruiting
- People taking part
- 51 people, planned
- Started
- 7 Jul 2026
- Expected to end
- 31 Jul 2027
- Type of study
- Observational
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at people aged 70 or older with metastatic colorectal cancer who have not yet had any treatment for the spread of the disease. They must have MSS, BRAF wild-type tumours and a G8 score of 12 or more.
- Age
- 70 to 99 years
- Sex
- All sexes can join.
- Disease stage
- Metastatic colorectal adenocarcinoma (colon cancer that has spread).
- Earlier treatment
- No treatment yet for the metastatic disease. Earlier (neo)adjuvant treatment with fluoroderivatives, with or without Oxaliplatin, is allowed.
- Biomarker or test result
- MSS tumour and BRAF WT (wild-type) tumour. G8 score of 12 or more.
Main reasons for not taking part
- MSI tumours
- BRAF V600E mutated tumours
- Not able to have doublet chemotherapy, by clinical decision
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted
- Age ≥ 70 years
- G8 score ≥ 12
- Patients with colorectal adenocarcinoma MSS
- Patients with BRAF WT colorectal adenocarcinoma
- Ability to understand and sign the informed consent form
Who cannot take part
- Patients not eligible for doublet chemotherapy by clinical decision
- Patients with MSI tumours
- Patients with BRAF V600E mutated tumours
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 70 and 99 years old?
This trial is currently available in Italy.
- E.O. Ospedali GallieraGenoa, ItalyContact: Davide S CorradengoNot yet recruiting
- E.O. Ospedali GallieraGenova, ItalyContact: Davide CORRADENGOTaking people
About the trial
What the trial wants to find out
In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.
The group in the trial
- Retrospective
PATIENTS AGED 70 YEARS AND OVER IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- RETROSPECTIVE OBSERVATIONAL STUDY OF CHEMOTHERAPY IN ELDERLY PATIENTS IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
- Plain-language title
- Reviews past records of older adults with spreading colon cancer receiving chemotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06840977, who can take part
- Record updated
- 16 July 2026